PROCEPT BioRobotics Corp. (PRCT)

PROCEPT BioRobotics' stock price declined by 49.12% between October 2024 and October 2025, reaching a 12-month low in October 2025. In Q1 2025, the company reported revenues of $69.2 million, a 55.5% year-over-year increase, and a GAAP loss of 45 cents per share. In Q2 2025, revenue grew 48% year-over-year to $79.18 million, with an EPS of ($0.35). The company is expected to announce its Q3 2025 results on November 4, 2025. The CEO stepped down in July 2025, with Larry Wood taking over. Analyst ratings are mixed, with a consensus of "Moderate Buy" and an average price target of $67.50 as of October 2025. Chicago Capital, LLC significantly increased its stake in PROCEPT BioRobotics in October 2025. A saline shortage in Q4 2024 impacted 10-20% of Aquablation procedures, but this disruption was resolved by Q2 2025.

The demand for PROCEPT BioRobotics' products and services can exhibit some seasonality. The fourth quarter of 2024 saw a slight sequential decline in revenue due to typical capital equipment seasonality. The timing of deal closures for new robotic systems can vary from quarter to quarter, influencing sales figures. The second quarter of 2025 was one of the most stable operating periods, following the resolution of a saline disruption.

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on advancing urological patient care through transformative solutions. Its primary product is the AquaBeam Robotic System, an image-guided surgical robotic system for minimally-invasive urologic surgery, initially targeting benign prostatic hyperplasia (BPH) via Aquablation therapy. The company also manufactures the HYDROS Robotic System, an AI-powered robotic technology that delivers Aquablation therapy, combining real-time imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation for precise prostate tissue removal.

PROCEPT BioRobotics operates in the United States and internationally. As of June 30, 2025, the U.S. installed base of robotic systems had grown to 595. The company focuses on direct sales to over 1,500 urology practices and 650 hospitals in the United States as of 2024. International revenue has shown significant growth, with strong sales momentum observed in the United Kingdom, Japan, and Korea during the second quarter of 2025.

PROCEPT BioRobotics has experienced both positive and negative events impacting its brand reputation. Positive events include FDA approval to initiate a pivotal study for prostate cancer and Breakthrough Device Designation for Aquablation therapy for prostate cancer. The company also received FDA 510(k) clearance for its HYDROS Robotic System and FDA-IDE approval for the WATER IV PCa prostate cancer study. A report in January 2025 challenged the company's technology, contributing to a stock price decline. Overall news sentiment is "Very Bullish," crowd wisdom is "Very Positive," and blogger sentiment is "Bullish."

PROCEPT BioRobotics has a diverse ownership structure, with institutional investors holding a significant portion of the company’s stock, ranging from approximately 39.17% to 89.46%. Major institutional owners include Fmr LLC, Vanguard Group Inc, BlackRock, Inc., Alliancebernstein L.p., Westfield Capital Management Co Lp, Chicago Capital, LLC, T. Rowe Price Investment Management, Inc., Price T Rowe Associates Inc /md/, Geode Capital Management, LLC, and State Street Corp. Individual and insider ownership accounts for approximately 3.06% of the stock, with CPMG Inc being the largest individual shareholder, owning 19.62% of the company. Retail investors hold approximately 42.56% of the stock.